"What is oncology and what does it involve?"

Oncology is the branch of medicine and life science dedicated to the study, diagnosis, and treatment of cancer. It encompasses the biological mechanisms behind tumour formation, the clinical approaches used to detect and manage the disease, and the laboratory research that drives new discoveries. The field spans multiple specialisations, from the molecular biology of cancer cells to the development of targeted therapies. The sections below address the most common questions researchers and life science professionals ask about oncology.

What are the main branches of oncology?

Oncology divides into several specialised branches, each focusing on a distinct aspect of cancer science. The three primary branches are medical oncology, surgical oncology, and radiation oncology. Beyond these clinical disciplines, the field also includes research-oriented branches such as molecular oncology, translational oncology, and experimental oncology, which are particularly relevant in laboratory and academic settings.

  • Medical oncology: focuses on systemic approaches to managing cancer, including chemotherapy, immunotherapy, and targeted therapy research
  • Surgical oncology: involves the physical removal of tumour tissue and is closely linked to pathology and staging
  • Radiation oncology: studies the effects of ionising radiation on tumour cells and surrounding tissue
  • Molecular oncology: examines the genetic and molecular alterations that drive cancer development, informing biomarker research and drug discovery
  • Translational oncology: bridges laboratory findings and their application in research models, accelerating the development of new investigational approaches
  • Paediatric oncology: addresses cancers that arise in children and adolescents, which often differ biologically from adult cancers

In the Benelux region, research institutions and biotech companies frequently work across several of these branches simultaneously, combining molecular insights with experimental models to advance understanding of cancer biology.

How does cancer develop at the cellular level?

Cancer develops when the normal regulatory mechanisms that control cell growth and division are disrupted, causing cells to proliferate uncontrollably. This process, known as oncogenesis or carcinogenesis, typically involves the accumulation of genetic mutations in key regulatory genes, including proto-oncogenes and tumour suppressor genes.

Under normal conditions, the cell cycle is tightly regulated by a series of checkpoints. When DNA damage occurs, these checkpoints pause the cycle to allow for repair or trigger programmed cell death, known as apoptosis. In cancer, mutations can disable these checkpoints, allowing damaged cells to survive and replicate.

Two categories of genes are central to this process. Proto-oncogenes, when mutated into oncogenes, send continuous growth signals even in the absence of the normal triggers. Tumour suppressor genes, when inactivated, remove the brakes on cell division. The combination of activated oncogenes and silenced suppressors is a hallmark of most cancers.

Additional factors that contribute to cancer development include epigenetic changes, which alter gene expression without changing the DNA sequence itself, and the tumour microenvironment, which can either restrain or support tumour growth depending on immune activity and surrounding tissue signals.

What methods do oncologists use to diagnose cancer?

Cancer diagnosis relies on a combination of imaging, molecular analysis, and tissue examination. No single method is sufficient on its own; accurate diagnosis requires integrating multiple data sources to determine the type, origin, and stage of the disease.

In research and clinical settings, the most commonly used diagnostic approaches include:

  1. Histopathology: microscopic examination of tissue biopsies remains the gold standard for confirming a cancer diagnosis and identifying tumour type
  2. Immunohistochemistry (IHC): uses antibodies to detect specific proteins in tissue samples, helping to characterise tumour markers and subtypes
  3. Molecular and genomic profiling: techniques such as next-generation sequencing (NGS) identify mutations, copy number variations, and gene expression patterns relevant to cancer biology
  4. Flow cytometry: analyses cell populations based on surface markers, widely used in haematological cancers
  5. Imaging technologies: including CT, MRI, and PET scans, used to assess tumour size, location, and spread
  6. Liquid biopsy: an emerging approach that detects circulating tumour DNA or cells in blood, offering a less invasive means of monitoring disease

In laboratory research environments, many of these diagnostic methods are adapted for experimental use, enabling researchers to study cancer models and validate new biomarkers under controlled conditions.

What are the most common cancer treatment approaches?

The most common cancer treatment approaches are surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. Each approach works through a different mechanism, and research increasingly focuses on combinations that may improve outcomes by addressing multiple aspects of tumour biology simultaneously.

From a research perspective, the distinction between these approaches is important because each involves different molecular targets and laboratory investigation methods.

Chemotherapy works by interfering with DNA replication, affecting rapidly dividing cells. Targeted therapies are designed to block specific molecular pathways that are dysregulated in particular cancer types, such as receptor tyrosine kinases or specific gene fusions. Immunotherapy is being investigated for its potential to enhance the body’s own immune response against tumour cells, with approaches including checkpoint inhibitors and adoptive cell transfer under active study.

Hormone therapy is another approach investigated in cancers that are driven by hormonal signals, such as certain breast and prostate cancers. Each of these approaches is studied extensively in laboratory settings before any investigational use, with oncology research providing the mechanistic foundation for understanding how and why they may be effective.

How is oncology research conducted in the laboratory?

Oncology research in the laboratory relies on a range of experimental models and analytical techniques designed to replicate and study cancer biology in a controlled environment. The primary research tools include cell culture systems, animal models, and increasingly, three-dimensional tissue models such as organoids.

Cell-based assays remain fundamental to oncology research. Researchers use cancer cell lines to study proliferation, migration, invasion, and response to experimental compounds. Multimode plate readers, imaging systems, and high-content analysis platforms are commonly used in these workflows to generate quantitative, reproducible data across large numbers of samples.

Organoid models represent a significant advance in oncology research methodology. These three-dimensional, self-organising structures derived from patient tissue or stem cells more accurately reflect the architecture and behaviour of real tumours than traditional two-dimensional cultures. Organoids are being used to study tumour development, investigate drug sensitivity, and model the tumour microenvironment in ways that were previously not possible.

Genomic and proteomic technologies play a central role in modern oncology research, enabling researchers to map the molecular landscape of tumours and identify potential targets. Liquid handling automation, high-throughput screening, and advanced microscopy are all integral to the throughput and reproducibility that contemporary oncology research demands.

What is the difference between benign and malignant tumours?

The key difference between benign and malignant tumours is that benign tumours do not invade surrounding tissue or spread to other parts of the body, while malignant tumours can. Malignancy is the defining characteristic of cancer; a tumour is classified as cancerous only when it is malignant.

Benign tumours grow locally and are typically encapsulated, meaning they remain contained within a defined boundary. They can cause problems if they press on nearby structures, but they do not infiltrate adjacent tissue and do not metastasise. Most benign tumours can be removed surgically without recurrence.

Malignant tumours, by contrast, have the capacity to invade neighbouring tissue and to shed cells that travel through the bloodstream or lymphatic system to establish secondary tumours, a process called metastasis. It is metastasis that makes cancer particularly difficult to study and treat, and it is a major focus of oncology research.

At the cellular level, malignant cells typically show greater genetic instability, altered morphology, and a loss of the differentiated characteristics of the tissue from which they originated. Understanding the molecular transitions that convert a benign proliferation into a malignant one is a central question in cancer biology.

How BioSPX supports oncology research in the Benelux

Life science researchers in Belgium, the Netherlands, and Luxembourg working in oncology require instruments that deliver precision, reproducibility, and the flexibility to support a wide range of experimental workflows. BioSPX provides an extensive portfolio of laboratory instruments tailored to these needs, backed by expert product specialists and a dedicated service department.

  • Multimode readers and imaging systems for cell-based oncology assays and high-content analysis
  • Liquid handling solutions that improve throughput and reproducibility in screening workflows
  • Organoid research platforms, including bioreactor systems for three-dimensional tumour model cultivation
  • Automation systems for routine cell culture tasks, reducing variability and freeing researchers’ time for analysis
  • Installation, user training, and maintenance support from specialists with deep application knowledge

Whether you are setting up a new oncology research workflow or looking to upgrade existing instrumentation, BioSPX’s team of product specialists can advise on the right configuration for your experimental goals. Contact BioSPX to discuss your oncology research requirements with a specialist.

Frequently Asked Questions

What is the difference between oncology and haematology, and do they overlap?

Oncology focuses on solid tumours and the broader science of cancer, while haematology specifically addresses diseases of the blood and bone marrow, including leukaemia, lymphoma, and myeloma. These fields overlap significantly because blood cancers are malignant by definition, meaning haematological oncology is a recognised subspecialty in its own right. In laboratory research, techniques such as flow cytometry are used across both disciplines, and many research groups working on haematological cancers operate within oncology departments or use shared infrastructure.

What is a tumour microenvironment, and why does it matter for research?

The tumour microenvironment (TME) refers to the complex ecosystem surrounding a tumour, including immune cells, blood vessels, fibroblasts, signalling molecules, and extracellular matrix components. It plays a critical role in regulating tumour growth, immune evasion, and response to therapy, meaning that studying cancer cells in isolation can give an incomplete picture. Researchers increasingly use advanced models such as organoids, co-culture systems, and three-dimensional scaffolds to better replicate the TME and generate more physiologically relevant data.

How do researchers choose between 2D cell culture and 3D organoid models for oncology experiments?

The choice depends on the experimental question, available resources, and the level of biological complexity required. Two-dimensional cell lines are well-established, cost-effective, and ideal for high-throughput screening, initial compound testing, and mechanistic studies where simplicity is an advantage. Three-dimensional organoid models are better suited to studies where tumour architecture, cell-cell interactions, or drug penetration dynamics are relevant, though they require more specialised equipment and protocols. Many research groups use both in a tiered approach, using 2D models for initial screening and 3D models for validation.

What are biomarkers in oncology, and how are they used in research?

Biomarkers in oncology are measurable biological indicators — such as specific proteins, gene mutations, or expression patterns — that provide information about the presence, progression, or behaviour of a cancer. In research settings, biomarkers are used to stratify experimental models, identify potential drug targets, and assess how cancer cells respond to investigational compounds. Techniques such as immunohistochemistry, next-generation sequencing, and multiplex protein assays are commonly used to detect and quantify biomarkers, and validating new biomarkers is itself a major area of oncology research.

What are the most common mistakes researchers make when setting up oncology cell-based assays?

One of the most frequent mistakes is failing to account for cell line authentication and mycoplasma contamination, both of which can significantly compromise data reliability and reproducibility. Researchers also sometimes underestimate the importance of passage number, as cancer cell lines can drift genetically over time and produce inconsistent results if not carefully managed. Inconsistent seeding density, insufficient replicates, and using endpoint assays when kinetic measurements would be more informative are other common pitfalls. Establishing standardised protocols and using validated reagents from the outset can prevent many of these issues.

How is liquid biopsy being used in oncology research, and what are its current limitations?

Liquid biopsy involves the detection and analysis of circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), or other tumour-derived materials in blood or other body fluids. In research, it is being investigated as a minimally invasive way to monitor tumour evolution, detect resistance mutations, and track treatment response over time. Current limitations include low sensitivity in early-stage cancers where circulating tumour material may be scarce, variability between detection platforms, and the challenge of distinguishing tumour-derived signals from background genomic noise. Standardisation of methods and validation across patient cohorts remain active areas of development.

What should a life science team consider when selecting laboratory instruments for an oncology research workflow?

Key considerations include the specific assay types the team will run — such as proliferation, apoptosis, migration, or genomic analysis — as well as the required throughput, level of automation, and compatibility with existing laboratory infrastructure. Reproducibility and data quality are particularly important in oncology research, where variability between experiments can obscure meaningful biological signals. It is also worth evaluating vendor support, including installation, training, and ongoing maintenance, especially for complex instruments such as high-content imaging systems or liquid handling platforms. Consulting with an application specialist before purchasing can help ensure the chosen configuration aligns with both current and anticipated experimental needs.

Related Articles

This content was generated with the help of AI and it may contain mistakes